Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

CANCER:

Gastroesophageal Cancer

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Related cancers:

‹

Gastric Cancer (780)

Gastroesophageal Junction Adenocarcinoma (185)

Gastric Adenocarcinoma (40)

Gastric Cancer (780)

Gastroesophageal Junction Adenocarcinoma (185)

Gastric Adenocarcinoma (40)

›

HER-2 positive	Gastroesophageal Cancer	HER-2 positive	Gastroesophageal Cancer	trastuzumab Sensitive: A2 - Guideline trastuzumab Sensitive : A2	trastuzumab Sensitive: A2 - Guideline trastuzumab Sensitive : A2
PD-L1 overexpression	Gastroesophageal Cancer	PD-L1 overexpression	Gastroesophageal Cancer	PD1 inhibitor Sensitive: B - Late Trials PD1 inhibitor Sensitive : B	PD1 inhibitor Sensitive: B - Late Trials PD1 inhibitor Sensitive : B
PD-L1 overexpression	Gastroesophageal Cancer	PD-L1 overexpression	Gastroesophageal Cancer	PD-L1 inhibitor Sensitive: B - Late Trials PD-L1 inhibitor Sensitive : B	PD-L1 inhibitor Sensitive: B - Late Trials PD-L1 inhibitor Sensitive : B
HER-2 amplification	Gastroesophageal Cancer	HER-2 amplification	Gastroesophageal Cancer	trastuzumab Sensitive: B - Late Trials trastuzumab Sensitive : B	trastuzumab Sensitive: B - Late Trials trastuzumab Sensitive : B
PD-L1 expression	Gastroesophageal Cancer	PD-L1 expression	Gastroesophageal Cancer	pembrolizumab Sensitive: C1 - Off-label pembrolizumab Sensitive : C1	pembrolizumab Sensitive: C1 - Off-label pembrolizumab Sensitive : C1
PD-L1 expression	Gastroesophageal Cancer	PD-L1 expression	Gastroesophageal Cancer	tislelizumab-jsgr Sensitive: C1 - Off-label tislelizumab-jsgr Sensitive : C1	tislelizumab-jsgr Sensitive: C1 - Off-label tislelizumab-jsgr Sensitive : C1
HER-2 positive	Gastroesophageal Cancer	HER-2 positive	Gastroesophageal Cancer	pembrolizumab + trastuzumab Sensitive: C1 - Off-label pembrolizumab + trastuzumab Sensitive : C1	pembrolizumab + trastuzumab Sensitive: C1 - Off-label pembrolizumab + trastuzumab Sensitive : C1
FGFR2 amplification	Gastroesophageal Cancer	FGFR2 amplification	Gastroesophageal Cancer	ABSK091 Sensitive: C2 – Inclusion Criteria ABSK091 Sensitive : C2	ABSK091 Sensitive: C2 – Inclusion Criteria ABSK091 Sensitive : C2
HER-2 positive	Gastroesophageal Cancer	HER-2 positive	Gastroesophageal Cancer	pembrolizumab Sensitive: C2 – Inclusion Criteria pembrolizumab Sensitive : C2	pembrolizumab Sensitive: C2 – Inclusion Criteria pembrolizumab Sensitive : C2
TP53 mutation	Gastroesophageal Cancer	TP53 mutation	Gastroesophageal Cancer	Immunotherapy Resistant: C3 – Early Trials Immunotherapy Resistant : C3	Immunotherapy Resistant: C3 – Early Trials Immunotherapy Resistant : C3
TET1 mutation	Gastroesophageal Cancer	TET1 mutation	Gastroesophageal Cancer	Immunotherapy Sensitive: C3 – Early Trials Immunotherapy Sensitive : C3	Immunotherapy Sensitive: C3 – Early Trials Immunotherapy Sensitive : C3
HER-2 expression	Gastroesophageal Cancer	HER-2 expression	Gastroesophageal Cancer	zanidatamab-hrii Sensitive: C3 – Early Trials zanidatamab-hrii Sensitive : C3	zanidatamab-hrii Sensitive: C3 – Early Trials zanidatamab-hrii Sensitive : C3